Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash & Equivalents: 2009-2025

Historic Revenue - Interest and Investment Income for Aytu Biopharma (AYTU) over the last 2 years, with Jun 2017 value amounting to $15.0 million.

  • Aytu Biopharma's Cash & Equivalents rose 62.27% to $32.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.6 million, marking a year-over-year increase of 62.27%. This contributed to the annual value of $31.0 million for FY2025, which is 54.71% up from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's Cash & Equivalents is $32.6 million, which was up 5.42% from $31.0 million recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's Cash & Equivalents registered a high of $49.9 million during Q2 2021, and its lowest value of $18.2 million during Q1 2025.
  • In the last 3 years, Aytu Biopharma's Cash & Equivalents had a median value of $20.0 million in 2024 and averaged $22.2 million.
  • Data for Aytu Biopharma's Revenue - Interest and Investment Income shows a maximum YoY slumped of 38.39% (in 2017) over the last 5 years.
  • Aytu Biopharma's Revenue - Interest and Investment Income (Quarterly) stood at $24.3 million in 2016, then crashed by 38.39% to $15.0 million in 2017.
  • Its Cash & Equivalents was $32.6 million in Q3 2025, compared to $31.0 million in Q2 2025 and $18.2 million in Q1 2025.